Product Description
Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645826/)
Mechanisms of Action: EP4 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | Malaysia | Norway | Poland | South Africa
Approved Indications: None
Known Adverse Events: None
Company: Arrys Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, Czech Republic, France, Germany, Hong Kong, Poland, Spain, United Kingdom, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Diabetic Cardiomyopathies
Phase 1: Colorectal Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AT-001-2001 | P3 |
Active, not recruiting |
Diabetic Cardiomyopathies |
2023-12-01 |
54% |
| ARYS-001 | P1 |
Completed |
Colorectal Cancer |
2023-03-07 |
27% |
| CTR20190801 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
|
| CTR20201261 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |